Orion has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family
(Thomson Reuters ONE) -
ORION CORPORATION STOCK EXCHANGE RELEASE 21 MARCH 2013 at 6.25
p.m. EET
Orion Corporation has submitted a marketing authorisation application for
combined budesonide-formoterol formulation of the Easyhaler® product family in
Europe. Orion applies for approval in European Union through decentralised
procedure. The review process will commence once all involved member states have
validated the application.
Orion Corporation
Timo Lappalainen Reijo Salonen
President and CEO SVP, Research and Development
Contact person:
Reijo Salonen, SVP, Research and Development, phone +358 50 966 3647
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE
[HUG#1687256]
Unternehmensinformation / Kurzprofil:
Datum: 21.03.2013 - 17:25 Uhr
Sprache: Deutsch
News-ID 242056
Anzahl Zeichen: 2166
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 135 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Orion has submitted a marketing authorisation application for combined budesonide-formoterol formulation of the Easyhaler® product family"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
